Immunotherapy: Open Access
Open Access

Melanoma Immunotherapy: Organizing the Immune System

Andrew Doey^{* *}Correspondence: Andrew Doey, Department of Immunology, Aston University, Birmingham, UK, Email:

Author info »

Description

Melanoma, a type of skin cancer arising from melanocytes, the cells responsible for producing melanin, which gives skin its color, poses a significant health challenge globally due to its aggressive nature and potential for metastasis. Treatments like surgery, chemotherapy and radiation therapy are commonly used, but the emergence of immunotherapy represents a revolutionary approach in cancer treatment [1].

Factors such as excessive Ultraviolet (UV) exposure, genetic predisposition and immunosuppression contribute to melanoma development. Early-stage melanomas are often treatable with surgery, but advanced stages with metastasis are notoriously challenging to manage, resulting in poor prognoses [2].

Mechanisms of melanoma immunotherapy

These include checkpoint inhibitors, Chimeric Antigen Receptor (CAR) T-cell therapy, cytokine therapy.

Checkpoint inhibitors: These biomarkers provide whether a patient is likely to respond to a specific immunotherapy treatment. They help identify individuals who are most likely to benefit from a particular therapy, thereby optimizing treatment selection and improving patient outcomes.

CAR-T cell therapy: Prognostic biomarkers gives information about the likely course of the disease in the absence of treatment. They help clinicians the overall outlook for a patient and to treat using adaptive methods [3].

Cytokine therapy: These biomarkers are used to assess treatment response and monitor disease progression during therapy. They provide real-time feedback on the effectiveness of treatment, enabling timely adjustments if necessary.

Current immunotherapies in melanoma

These include Programmed Death 1 (PD-1) inhibitors, Cytotoxic T-Lymphocyte associated Antigen 4 (CTLA-4) inhibitors, combination therapies and adoptive cell therapy [4].

PD-1 inhibitors: By blocking PD-1, pembrolizumab restores T cell activity against melanoma cells, leading to improved outcomes in both treatment-naïve and previously treated patients.

CTLA-4 inhibitors: CTLA-4 inhibition enhances T cell activation, promoting immune-mediated tumor regression.

Combination therapies: Dual checkpoint blockade (e.g., ipilimumab plus nivolumab) has shown enhanced efficacy compared to monotherapy, albeit with increased risk of immune-related adverse events.

Adoptive cell therapy: CAR-T cell therapy, though still in early stages for melanoma, hold the potential for personalized treatment approaches [5-7].

Challenges

Melanoma immunotherapy faces several challenges which are as follows.

Resistance: Some tumors develop resistance mechanisms, limiting treatment efficacy over time.

Toxicity: Immune-related adverse events, though manageable, can be severe and require vigilant monitoring and intervention.

Cost: Immunotherapies are expensive, posing economic challenges for widespread adoption [8,9].

Future directions and research

Ongoing research aims to address these challenges and expand treatment options.

Biomarker discovery: Identifying predictive biomarkers can enhance patient selection and personalize treatment strategies.

Targeted therapies: Investigating novel targets and combinations to overcome resistance and improve treatment outcomes [10].

Enhancing safety profiles: Developing strategies to mitigate immune-related adverse events without compromising efficacy.

Combination therapies: Exploring synergistic combinations of immunotherapies with other treatment modalities like targeted therapy or chemotherapy.

Conclusion

In conclusion, melanoma represents a health threat due to its nature for metastasis. While various treatments like surgery, chemotherapy, etc., are commonly using, the immunotherapy marks a revolutionary shift in melanoma management. Immunotherapeutic approaches control the body's immune system to combat cancer cells effectively. However, challenges such as resistance development, immune-related toxicities, underscore the complexity of integrating immunotherapy into standard therapy. Ongoing study focusing on biomarker identification, novel targets and combination therapies aims to enhance treatment efficacy and broaden therapeutic options.

Looking ahead, continued advancements in immunotherapy hold potential for improving outcomes in melanoma patients, potentially transforming the cancer treatment through personalized and targeted approaches.

References

1. Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: Overall results of a randomized trial of the Southwest oncology group. J Clin Oncol. 2002;20(8):2058-2066.

   [Crossref] [Google Scholar] [PubMed]

2. Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer. 1995;75(S2):726-734.

   [Crossref] [Google Scholar] [PubMed]

3. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol. 1998; 25(6):623-635.

   [Google Scholar] [PubMed]

4. Morton DL, Hoon DS, Nizze JA, Foshag LJ, Famatiga E, Wanek LA, et al. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann N Y Acad Sci. 1993;690(1):120-134.

   [Crossref] [Google Scholar] [PubMed]

5. Hauschild A, Weichenthal M, Balda BR, Becker JC, Wolff HH, Tilgen W, et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate-and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol. 2003;21(15):2883-2888.

   [Crossref] [Google Scholar] [PubMed]

6. Von Rohr A, Ghosh AK, Thatcher N, Stern PL. Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. Br J Cancer. 1993;67(1):163-171.

   [Crossref] [Google Scholar] [PubMed]

7. Pectasides D, Dafni U, Bafaloukos D, Skarlos D, Polyzos A, Tsoutsos D, et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol. 2009;27(6):939-944.

   [Crossref] [Google Scholar] [PubMed]

8. Eggermont AM. The role interferon-alpha in malignant melanoma remains to be defined. Eur J Cancer. 2001;37(17):2147-2153.

   [Crossref] [Google Scholar] [PubMed]

9. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: A randomised trial. Lancet. 2001;358(9285):866-869.

   [Crossref] [Google Scholar] [PubMed]

10. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials. J Clin Oncol. 2002;20(7):1818-1825.

    [Crossref] [Google Scholar] [PubMed]